Select a medication above to begin.
Trijardy XR
empagliflozin/ linagliptin/ metformin
Black Box Warnings .
Lactic Acidosis
post-marketing cases of hypothermia, hypotension, resistant bradyarrhythmias, and death; onset may be subtle with nonspecific symptoms including malaise, myalgias, respiratory distress, somnolence, abdominal pain; lab findings include lactate >5 mmol/L, anion gap acidosis (without evidence of ketonuria or ketonemia), incr. lactate/pyruvate ratio, metformin level >5 mcg/mL; risk factors may include renal impairment, concomitant meds, patients 65 yo and older, radiocontrast study, any surgery, hypoxemia, excessive acute or chronic alcohol intake, or hepatic insufficiency; D/C metformin immediately if lactic acidosis suspected, hospitalize patient and institute general supportive care, prompt HD recommended
Adult Dosing .
Dosage forms: TAB: 5 mg IR/2.5 mg IR/1000 mg ER, 10 mg IR/5 mg IR/1000 mg ER, 12.5 mg IR/2.5 mg IR/1000 mg ER, 25 mg IR/5 mg IR/1000 mg ER
diabetes mellitus, type 2
- [conversion from metformin with or without linagliptin]
- Dose: 1-2 tabs PO qam; Start: empagliflozin 10 mg/linagliptin 5 mg PO qam with current total daily metformin dose PO qam; Max: 25 mg/5 mg/2000 mg/day; Info: give with meal; do not cut/crush/chew tab; hold tx at least 3 days before surgery/procedure if prolonged fasting; D/C for iodinated contrast study if eGFR <60, hepatic disease history, alcoholism history, heart failure history, or receiving contrast intra-arterially; restart after 48h if stable renal function; see empagliflozin for cardiovascular event risk reduction use, heart failure risk reduction use, or kidney disease progression and cardiovascular-associated risk reduction use
- [conversion from metformin plus empagliflozin with or without linagliptin]
- Dose: 1-2 tabs PO qam; Start: current total daily empagliflozin dose PO qam with linagliptin 5 mg PO qam with current total daily metformin dose PO qam; Max: 25 mg/5 mg/2000 mg/day; Info: give with meal; do not cut/crush/chew tab; hold tx at least 3 days before surgery/procedure if prolonged fasting; D/C for iodinated contrast study if eGFR <60, hepatic disease history, alcoholism history, heart failure history, or receiving contrast intra-arterially; restart after 48h if stable renal function; see empagliflozin for cardiovascular event risk reduction use, heart failure risk reduction use, or kidney disease progression and cardiovascular-associated risk reduction use
renal dosing
- [see below]
- eGFR 30-44: avoid tx initiation; eGFR <30: contraindicated; Info: weigh risk/benefit if eGFR 30-44 during tx
- HD/PD: avoid use
hepatic dosing
- [see below]
- hepatic impairment: avoid use
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.